US Pharma MarketingEven though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
Sarepta tumbles as its gene therapy sales decline further
Sarepta tumbles as its gene therapy sales decline further is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: BioPharma Dive